<DOC>
	<DOCNO>NCT01396408</DOCNO>
	<brief_summary>This research do treatment cure type cancer . Although type chemotherapy cause cancer shrink time , good option need .</brief_summary>
	<brief_title>A Phase II Study Sunitinib Temsirolimus Patients With Advanced Rare Tumours</brief_title>
	<detailed_description>The purpose study find effect study drug - sunitinib temsirolimus - type cancer . The study begin find sunitinib shrink cancer . If sunitinib work , temsirolimus test next .</detailed_description>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Eligibility Criteria ALL Patients Patients must histologically cytologically confirm diagnosis rare tumour follow : 1 . Vascular sarcoma : Angiosarcoma , hemangiosarcoma , hemangiopericytoma , hemangioblastomas ; 2 . Clear cell carcinoma ovary , endometrium ; 3 . Medullary thyroid carcinoma ; 4 . Neuroendocrine tumour : paragangliomas pheochromocytoma ; 5 . Adrenocorticocarcinoma ; 6 . Thymic carcinoma ; 7 . Fibrolamellar hepatocellular carcinoma ; 8 . Exploratory genetic cohort sunitinib : Rare tumour somatic germline mutation sunitinib target VEGFR , PDGFR , KIT , RET ; 9 . Exploratory genetic cohort temsirolimus : Rare tumour arise know suspected germline mutation mTOR pathway PTEN , TS1/2 , LKB1 , NF1/2 somatic mutation mTOR pathway mutation amplification P13K AKT ; 10 . Unspecified cohort exploratory evaluation . The unspecified histology must also rare tumours traditional phase II clinical trial clinical activity laboratory data support likely sensitivity agent . 11 . Ewing 's Sarcoma Family Tumours ( ESFT ) relapse refractory . Patients must unresectable , locally advanced metastatic disease know life prolong standard therapy . Patients must tumour tissue primary tumour available Presence clinically and/or radiologically documented disease . At least one site disease must unidimensionally measurable follow : Chest xray ≥ 20 mm Ct scan ( slice thickness ≤ 5 mm ) ≥ 10 mm &gt; Longest diameter Physical exam ( use caliper ) ≥ 10 mm Lymph node ct scan ≥ 15 mm &gt; Measured short axis All radiology study must perform within 21 day prior registration ( within 28 day negative ) . Age ≥ 16 year cohorts # 110 ; age ≥ 5 year cohort # 11 ( ESFT ) . Patients must life expectancy least 12 week . ECOG performance status 0 , 1 2 . Previous Therapy Chemotherapy : Patients may receive prior chemotherapy ( limit number prior regimen ) , however prior treatment relevant mTOR VEGFR , KIT , RET , PDGFR inhibitor permit ( i.e . eligible sunitinib : prior treatment VEGFR , KIT , RET PDGFR inhibitor permit ; eligible temsirolimus : prior treatment mTOR inhibitor permit ) . A minimum 28 day ( 4 week ) must elapse since last dose chemotherapy prior registration . Patients must recover treatment related toxicity prior registration . Radiation : Patients may prior radiation therapy . A minimum 28 day ( 4 week ) since last dose radiation must elapse prior registration ( exception may make low dose , palliative radiotherapy . Patients must recover acute toxic effect radiation prior registration . Previous surgery : permit provide wound healing occur least 28 day elapse prior registration surgery major . Laboratory Requirements : ( must do within 7 day prior registration ) Hematology Absolute granulocyte : ≥ 1.5 x 10^9/L Platelets : ≥ 100 x 10^9/L Chemistry : ALL Patients Bilirubin ≤ 1.5 x UNL ( upper normal limit ) AST ALT ≤ 2.5 x UNL Serum Creatinine ≤UNL : Creatinine clearance ≥ 60ml/min Chemistry : TEMSIROLIMUS Arm Only Fasting cholesterol ≤ 9.0 mmol/L Fasting triglycerides ≤ 4.56 mmol/L * Creatinine clearance measure directly 24 hour urine sampling calculate Cockcroft Formula : Females : GFR = 1.04 x ( 140age ) x weight kg serum creatinine μmol/L Males : GFR = 1.23 x ( 140age ) x weight kg serum creatinine μmol/L Patient guardian consent must obtain patient accord local Institutional and/or University Human Experimentation Committee requirement . Children &gt; 8 year old whose parent guardian sign consent behalf may also sign assent desire . It responsibility local participate investigator obtain necessary local clearance , indicate write NCIC CTG Study Coordinator clearance obtain , trial commence centre . Because differ requirement , standard consent form trial provide sample form provide . A copy initial full board REB approval approve consent form must send central office . The patient parent/legal guardian must sign consent form prior registration . Please note consent form study must contain statement give permission NCIC CTG monitoring agency review patient record . Patients must accessible treatment , response assessment followup . Patients register trial must treat follow participate centre . This imply must reasonable geographical limit ( example : 1 ½ hour 's driving distance ) place patient consider trial . ( Call NCIC CTG office 6135336430 question arise regard interpretation criterion . ) Investigators must assure patient registered trial available complete documentation treatment , adverse event , followup . In accordance NCIC CTG policy , protocol treatment begin within 5 work day patient registration . Ineligibility Criteria ALL Patients Patients fulfill follow criterion eligible admission either sunitinib treatment arm ( Arm A ) temsirolimus arm ( Arm B ) study : Patients history malignancy , except : adequately treat nonmelanoma skin cancer solid tumour curatively treat evidence disease ≥ 3 year . Patients prior treatment relevant mTOR VEGFR , KIT , RET , PDGFR inhibitor . Patients prior treatment mTOR inhibitor ineligible temsirolimus ; patient prior treatment VEGFR , KIT , RET PDGFR inhibitor ineligible sunitinib . Pregnant lactating woman . Women childbearing potential must urine pregnancy test proven negative within 7 day prior registration . Men woman childbearing potential must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Patients know symptomatic brain metastasis ( brain CT necessary rule brain metastasis , unless clinical suspicion CNS involvement ) . Patients treat radiologic clinical evidence stable brain metastasis , evidence cavitation hemorrhage brain lesion , eligible provide asymptomatic require corticosteroid ( must discontinue steroid least 1 week prior entry ) . Patients know hypersensitivity relevant study drug component , compound similar chemical biologic composition . Patients receive concurrent treatment anticancer therapy investigational agent . Patients serious illness medical condition would permit patient manage accord protocol include , limited : 1 . History significant neurologic psychiatric disorder would impair ability obtain consent limit compliance study requirement 2 . Active uncontrolled infection 3 . Any medical condition might aggravate treatment 4 . Serious nonhealing wound , ulcer , bone fracture . 5 . Abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 28 day treatment . Patients believe high risk fistula formation location extent disease enrol . Ineligibility Criteria SUNITINIB Arm Only Patients fulfill follow criterion eligible admission sunitinib treatment arm ( Arm A ) study : Patients preexist cardiovascular condition and/or symptomatic cardiac dysfunction follow : 1 . QTc prolongation ( define QTc interval equal great 500 msec ) significant abnormality screen ECG ( require within 14 day prior registration ) . 2 . Current history Class III IV heart failure define NYHA functional classification system . 3 . Patients prior anthracycline exposure , previous central thoracic radiation include heart radiation port , history NYHA Class II cardiac function UNLESS currently asymptomatic respect cardiac function AND leave ventricular ejection fraction ( LVEF ) &gt; low limit normal ( LLN ) institution assess screen MUGA ECHO ( require within 14 day prior registration ) . 4 . Poorly control hypertension ( systolic blood pressure ≥ 140 mmHg diastolic blood pressure ≥ 90 mmHg . 5 . Myocardial infarction , cardiac arrhythmia , stable/unstable angina , symptomatic congestive heart failure , coronary/peripheral artery bypass graft stenting within 12 month prior study entry 6 . History pulmonary embolism within past 12 month ; patient incidental pulmonary embolus find routine scanning &gt; 6 month prior registration may eligible . 7 . History cerebrovascular accident ( CVA ) transient ischemic attack within 12 month prior study entry . Patients require use therapeutic dos coumadinderivative anticoagulant warfarin exclude , although dos 2 mg daily permit prophylaxis thrombosis . Use low molecular weight heparin permit provided patient 's INR ≤ 1.5 . INR screen coagulation ( require within 7 day prior registration ) . Patients bowel obstruction GI tract disease result inability absorb oral medication , uncontrolled inflammatory GI disease ( e.g . Crohn 's disease , ulcerative colitis ) post surgical malabsorption characterize uncontrolled diarrhea result weight loss vitamin deficiency require IV hyperalimentation ; condition would preclude compliance oral medication . Patients preexist hypothyroidism ineligible , unless euthyroid medication . Inability discontinue drug know potent inhibitor inducer cytochrome P450 ( CYP3A4 ) . Patients must medications 712 day prior first dose sunitinib . Inhibitors prohibit 7 day dose study . azole antifungal ( ketoconazole , itraconazole , miconazole , fluconazole ) HIV protease inhibitor ( indinavir , saquinavir , ritonavir , atazanavir , nelfinavir ) clarithromycin verapamil erythromycin delavirdine diltiazem nefazodone telithromycin Inducers prohibit 12 day dose study . rifampin phenytoin rifabutin St. John 's wort carbamazepine efavirenz phenobarbital tipranavir</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>